DS
ABUS icon

DRW Securities’s Arbutus Biopharma ABUS Stock Holding History

DRW Securities’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$311K Buy
+69,089
New +$302K ﹤0.01% 872

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

DRW Securities's ABUS Position: Q1 2026 in Review

DRW Securities opened a new position in Arbutus Biopharma (ABUS) in Q1 2026: 69,089 shares worth $311K. The stake represents ﹤0.01% of the portfolio and ranks #872 among its holdings.

167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • DRW Securities held 69,089 shares of Arbutus Biopharma worth $311K as of Q1 2026.
  • Arbutus Biopharma was a new DRW Securities position in Q1 2026.
  • Arbutus Biopharma made up ﹤0.01% of DRW Securities's portfolio in Q1 2026, its #872 holding.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.